Aberdeen Group plc reduced its stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 67.4% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 210,659 shares of the company's stock after selling 436,284 shares during the period. Aberdeen Group plc owned about 0.32% of Oruka Therapeutics worth $17,546,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Legal & General Group Plc purchased a new stake in Oruka Therapeutics in the 2nd quarter valued at $2,874,000. Sei Investments Co. lifted its stake in Oruka Therapeutics by 136.0% during the 1st quarter. Sei Investments Co. now owns 22,840 shares of the company's stock valued at $1,120,000 after acquiring an additional 13,164 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Oruka Therapeutics by 517.1% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 104,310 shares of the company's stock worth $9,927,000 after acquiring an additional 87,408 shares during the last quarter. Braidwell LP purchased a new position in Oruka Therapeutics during the 2nd quarter worth $26,473,000. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Oruka Therapeutics in the 1st quarter worth $5,543,000. 56.44% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Oruka Therapeutics
In other news, CEO Lawrence Klein sold 75,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the completion of the sale, the chief executive officer owned 925,580 shares in the company, valued at $84,996,011.40. This trade represents a 7.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $104.97, for a total transaction of $1,049,700.00. Following the sale, the senior vice president owned 14,219 shares of the company's stock, valued at approximately $1,492,568.43. The trade was a 41.29% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 197,950 shares of company stock valued at $18,288,360 over the last quarter. 23.49% of the stock is currently owned by insiders.
Analyst Ratings Changes
Several research firms have commented on ORKA. Weiss Ratings reiterated a "sell (d-)" rating on shares of Oruka Therapeutics in a research note on Tuesday, October 13th. Wedbush reissued an "outperform" rating and set a $165.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. Piper Sandler restated an "overweight" rating on shares of Oruka Therapeutics in a research note on Wednesday, October 7th. Mizuho set a $120.00 target price on Oruka Therapeutics in a report on Thursday, September 3rd. Finally, Wall Street Zen lowered Oruka Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, August 16th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Oruka Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $141.80.
Check Out Our Latest Research Report on ORKA
Oruka Therapeutics Price Performance
Shares of NASDAQ:ORKA opened at $96.32 on Wednesday. The company's 50-day moving average is $89.85 and its 200 day moving average is $72.99. Oruka Therapeutics, Inc. has a fifty-two week low of $25.23 and a fifty-two week high of $115.51.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). On average, analysts predict that Oruka Therapeutics, Inc. will post -2.52 earnings per share for the current fiscal year.
About Oruka Therapeutics
(
Free Report)
Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company's pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.